Vol. 5 No. 8 (2025)
Reimbursement Recommendations

Dupilumab (Dupixent)

decorative image of the issue cover

Published August 5, 2025

Key Messages

  • Canada’s Drug Agency (CDA-AMC) recommends that Dupixent be reimbursed by public drug plans for the treatment of adult patients with moderate-to-severe prurigo nodularis (PN) whose disease is not adequately controlled with topical prescription therapies or when those therapies are not advisable, if certain conditions are met.
  • Dupixent should only be covered to treat adult patients with moderate-to-severe PN who have been diagnosed by a dermatologist, have severe itching (based on a Worst Itch Numeric Rating Scale score of 7 or higher), have at least 20 PN lesions on both sides of the body, and have tried topical prescription therapies and had an inadequate response.
  • Dupixent should only be reimbursed if the patient is under the care of a dermatologist who has expertise in the management of PN, and if the cost of Dupixent is reduced. When first prescribed, Dupixent should only be reimbursed for 6 months. Dupixent should not be used in combination with other systemic therapies for PN.